Trial Profile
Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pierre Fabre
- 02 Feb 2019 Status changed from recruiting to completed.
- 12 May 2011 New trial record